Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Adempas / Verquvo (sGC stimulator alliance with Bayer by Year
Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)
Merck Adempas / Verquvo (sGC stimulator alliance with Bayer: 13.0% in FY2025, unchanged from a year earlier.
Where the FY2025 figure comes from
“|| Alliance Revenue - Adempas/Verquvo (5) | 106 | 123 | 112 | 129 | 470 | 98 | 106 | 102 | 109 | 415 | 18 | 18 | 13 | 13”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.0% | 0.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 13.0% | +5.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 8.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 22.0% | -16.0 pts | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 38.0% | – | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
Cite this data
StockData. (2026). Merck Adempas / Verquvo (sGC stimulator alliance with Bayer (%), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-adempas-verquvo-ww-exfx-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.